Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

Conditions

Cardiovascular Disease

Brief summary

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

Chemello K, Gallo A, Guedon AF, Techer R, Croyal M, Swietek MJ, Meilhac O, Amarenco P, Lambert G.

2023-08-225 citations

10.1016/j.jacadv.2023.100557

Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.

Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM, SPARCL Committees and Investigators.

2020-03-1628 citations

10.1016/j.jacc.2020.03.015

Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials.

Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD.

2019-05-0118 citations

10.1161/jaha.118.010827

Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks

Peter Ganz, Pierre Amarenco, Larry B. Goldstein, Henrik Sillesen, Weihang Bao et al. (7 authors)

Stroke2017-11-0737 citations

10.1161/strokeaha.117.017965

Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.

Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S, SPARCL Trial Investigators.

2017-01-0145 citations

10.1016/j.jacc.2016.10.057

Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial

Pierre Amarenco, Alfred Callahan, Vito M. Campese, Larry B. Goldstein, Michael G. Hennerici et al. (10 authors)

Stroke2014-08-2233 citations

10.1161/strokeaha.114.005832

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM, SPARCL Investigators.

2011-06-1369 citations

10.1001/archneurol.2011.146

High-dose atorvastatin after stroke or transient ischemic attack.

Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.

2006-08-011,860 citations

10.1056/nejmoa061894

Interventions

DRUGatorvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Previous stroke or TIA

Exclusion criteria

* coronary heart disease

Design outcomes

Primary

Measure	Time frame
Time to occurrence of fatal or non-fatal stroke	—

Secondary

Measure	Time frame
Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.	—
Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.	—

Countries

Australia, Austria, Belgium, Brazil, Chile, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Portugal, Slovakia, South Africa, Spain, Sweden, Switzerland, United Kingdom, Venezuela

Outcome results

None listed